Please assess the completion status of the following clinical trial:

Trial Title: Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is \>18 years and male or female of any race / ethnicity~* Patient or patient's legally acceptable representative provides written informed consent and is willing to comply with protocol procedures~* Patient must have histopathologically confirmed head/neck, lung, liver, rectal or cervical cancer with tumor size ≥ 3cm~* Patient has tumor tissue samples available before treatment for future immunohistochemistry biomarker tests (HIF1alpha and CA-IX)~* Patient is scheduled to have or already had a clinical \[F 18\]FDG PET/CT scan recommended to be within 14 days of the first pre-treatment \[F 18\]HX4 PET/CT scan and have no treatment intervention in between these two scans~* Patient is scheduled or is intended to be scheduled to receive chemotherapy, radiation or chemoradiotherapy treatment(s) after the pre-treatment \[F 18\]HX4 PET/CT and \[F 18\]FDG PET/CT scans for his/her cancer care~* Patient must have hepatic and renal functions as defined by laboratory results within the following ranges:~  * Total bilirubin within 2 times institutional upper limit of normal~ * AST (SGOT) and ALT (SGPT) ≤ 2.5 times institutional upper limits of normal~ * Serum creatinine ≤ 2.5 times institutional limit of normal~ * BUN within 2 times institutional upper limit of normal~Exclusion Criteria:~* Patient is not capable of complying with study procedures~* Female patient is pregnant or nursing~  o Exclude the possibility of pregnancy by one of the following:~ * Confirming in medical history that the patient is post-menopausal for a minimum of one year, or surgically sterile~ * Confirming the patient is using one of the following methods of birth control for a minimum of one month prior to entry into this study: IUD, oral contraceptives, Depo-Provera, or Norplant~ * Confirming a negative urine dipstick test taken the morning of but before receiving \[F 18\]HX4~* Patient has been involved in an investigative, radioactive research procedure within 7 days and during the study participation period~* Patient has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- [F 18]HX4 (Type: EXPERIMENTAL): \[F18\]HX4, 10 mCi, is administered in a single intravenous bolus injection, followed by a saline flush.

Based on this trial design, predict the completion outcome and termination type (if applicable).